Patents by Inventor Thomas Emrich
Thomas Emrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230265177Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: ApplicationFiled: December 29, 2022Publication date: August 24, 2023Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
-
Publication number: 20230251270Abstract: Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.Type: ApplicationFiled: April 21, 2023Publication date: August 10, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Hubert Kettenberger, Wolfgang Richter, Laurent Lariviere, Thomas Kraft, Thomas Emrich
-
Patent number: 11668722Abstract: Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.Type: GrantFiled: October 18, 2019Date of Patent: June 6, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Hubert Kettenberger, Wolfgang Richter, Laurent Lariviere, Thomas Kraft, Thomas Emrich
-
Publication number: 20230147561Abstract: Implementations generally relate to metaverse content modality mapping. In some implementations, a method includes obtaining functionality developed for a first modality of a virtual environment. The method further includes mapping the functionality to a second modality of the virtual environment. The method further includes executing the functionality developed for the first modality based on user interaction associated with the second modality.Type: ApplicationFiled: November 7, 2022Publication date: May 11, 2023Inventors: Erik Murphy-Chutorian, Nicholas Butko, Thomas Emrich, Joel Udwin, Rigel Gareth Benton, Christoph Michael Bartschat
-
Patent number: 11572404Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: GrantFiled: September 17, 2020Date of Patent: February 7, 2023Assignee: Hoffman-La Rocher Inc.Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
-
Publication number: 20220073593Abstract: Herein is reported a method for providing a modified antibody with improved in vivo half-live, comprising the modification of the Fc-region of the antibody by introducing one or more mutations that change the binding of the Fc-region to human FcRn until the (relative) retention time of the modified antibody in an FcRn affinity chromatography is increased for more than 1 minute but not more than 5 minutes compared to the parent antibody.Type: ApplicationFiled: April 22, 2021Publication date: March 10, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Thomas EMRICH, Hubert KETTENBERGER, Thomas KRAFT, Wolfgang RICHTER, Tilman SCHLOTHAUER
-
Publication number: 20210190795Abstract: Herein is reported a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life comprising the steps of a) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a first sodium chloride concentration, and b) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a second sodium chloride concentration, whereby the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life is determined if the retention time determined in step a) and the retention time determined in step b) are substantially different.Type: ApplicationFiled: January 26, 2021Publication date: June 24, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Thomas Emrich, Hubert Kettenberger, Tilman Schlothauer, Angela Schoch
-
Publication number: 20210139571Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: ApplicationFiled: September 17, 2020Publication date: May 13, 2021Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
-
Patent number: 10822402Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: GrantFiled: December 5, 2017Date of Patent: November 3, 2020Assignee: HOFFMANN-LA ROCHE INC.Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
-
Publication number: 20200217851Abstract: Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.Type: ApplicationFiled: October 18, 2019Publication date: July 9, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Hubert Kettenberger, Wolfgang Richter, Laurent Lariviere, Thomas Kraft, Thomas Emrich
-
Patent number: 10040843Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.Type: GrantFiled: April 27, 2016Date of Patent: August 7, 2018Assignee: ROCHE GLYCART AGInventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
-
Publication number: 20180079804Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: ApplicationFiled: December 5, 2017Publication date: March 22, 2018Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
-
Patent number: 9862763Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: GrantFiled: June 22, 2016Date of Patent: January 9, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
-
Publication number: 20170227547Abstract: Herein is reported a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life comprising the steps of a) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a first sodium chloride concentration, and b) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a second sodium chloride concentration, whereby the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life is determined if the retention time determined in step a) and the retention time determined in step b) are substantially different.Type: ApplicationFiled: September 20, 2016Publication date: August 10, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Thomas Emrich, Hubert Kettenberger, Tilman Schlothauer, Angela Schoch
-
Publication number: 20160376352Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: ApplicationFiled: June 22, 2016Publication date: December 29, 2016Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
-
Publication number: 20160340413Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.Type: ApplicationFiled: April 27, 2016Publication date: November 24, 2016Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
-
Patent number: 9346872Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.Type: GrantFiled: August 5, 2013Date of Patent: May 24, 2016Assignee: ROCHE GLYCART AGInventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
-
Patent number: 9273361Abstract: The present invention relates to a method for the specific detection and/or identification of Enterococcus species, in particular Enterococcus faecalis and/or Enterococcus faecium, using new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region. The present invention relates also to said new nucleic acid sequences derived from the ITS region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of Enterococcus species, in particular of Enterococcus faecalis and/or Enterococcus faecium, in a biological sample. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Enterococcus species in a sample.Type: GrantFiled: January 23, 2013Date of Patent: March 1, 2016Assignees: FUJIREBIO EUROPE N.V., ROCHE DIAGNOSTICS GMBHInventors: Hilde De Henau, Joachim Van Crombruggen, Geert Jannes, Gerd Haberhausen, Thomas Emrich
-
Publication number: 20150218244Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). More particularly, the invention concerns fusion proteins of antibodies and mutant IL-10 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of inflammatory diseases. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.Type: ApplicationFiled: February 4, 2015Publication date: August 6, 2015Inventors: Thomas Emrich, Pablo Umana, Ekkehard Moessner, Ralf Hosse, Jens Fischer, Lydia Jasmin Hanisch, Daigen Xu
-
Patent number: 8945850Abstract: The present invention relates to a method for the specific detection and/or identification of Staphylococcus species, in particular Staphylococcus aureus, using new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region. The present invention relates also to said new nucleic acid sequences derived from the ITS region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of Staphylococcus species, in particular of S. aureus, in a biological sample. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Staphylococcus species in a sample.Type: GrantFiled: April 18, 2008Date of Patent: February 3, 2015Assignees: Fujirebio Europe N.V., Roche Diagnostics GmbHInventors: Sofie Claeys, Geert Jannes, Gerd Haberhausen, Thomas Emrich, Lia Verdoodt